Binding Site Showcases Optilite System for Special Protein Testing

Binding Site (Birmingham, UK) is showcasing its Optilite system, the leading solution for multiple myeloma and immune status testing, at the 2023 EuroMedLab Congress.

Optilite represents a significant breakthrough in special protein testing. The innovative system has been fully optimized to simplify complex analytical processes, delivering unparalleled efficiency, workflow optimization, and confidence in test results. With an array of intelligent features, Optilite sets a new standard in the protein laboratory field by seamlessly integrating cutting-edge technology and advanced software.

At EuroMedLab Rome 2023, Binding Site is also presenting its range of in vitro assays, which have received the CE mark for Europe, FDA clearance for the USA, and approval from regulatory authorities in multiple countries. These comprehensive assays cover all five isotypes of immunoglobulins, offering a complete solution. Among the assays being highlighted by Binding Site at the industry event are Freelite and Hevylite, which provide a comprehensive monitoring solution for managing patients with multiple myeloma.

The Freelite assay has significantly enhanced laboratory and clinical practices in the detection and follow-up of monoclonal gammopathies. The Optilite Freelite assay, FDA-cleared for aiding in the diagnosis and monitoring of multiple myeloma, represents the state-of-the-art in free light chain testing. Additionally, Hevylite is a unique immunoassay panel designed to accurately identify and quantify immunoglobulin heavy and light chain isotypes. Together, these advancements by Binding Site contribute to the advancement of diagnostic and monitoring capabilities in the field of multiple myeloma.

Related Links:
Binding Site